Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

$210.8M

Market Cap • 12/26/2024

2015

(9 years)
Founded

2024

IPO

NASDAQ

Listing Exchange
Flag of US

Richmond

Headquarters • California